Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02552953 | A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers | PHASE1 | COMPLETED | 60 | — | — | Sep 28, 2015 | Aug 25, 2023 | May 31, 2024 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| CYC065 - 4 hour infusion (Part 1 completed) | EXPERIMENTAL | CYC065 will be administered by 4 -hour infusion every 3 weeks. |
| CYC065 - 1 hour infusion (Part 2 - ongoing) | EXPERIMENTAL | CYC065 will be administered by 1 - hour infusion on Days 1, 2, 8, and 9 every 3 weeks |
| CYC065 - Oral (Part 3 - ongoing) | EXPERIMENTAL | CYC065 will be administered orally on Days 1, 2, 8 and 9 every 3 weeks |
| Name | Type | Description |
|---|---|---|
| CYC065 | DRUG | - |
Inclusion Criteria: * Histologically or cytologically confirmed solid tumors or lymphomas that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective * 18 years or older * ECOG performance status 0-1 * Life expectancy ≥ 3 months ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520 / GEH200521 - Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | — | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |